Alicia Grande - Mar 28, 2023 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
VP, Treasurer and CFO
Signature
/s/ Alicia Grande
Stock symbol
CPRX
Transactions as of
Mar 28, 2023
Transactions value $
-$1,695,395
Form type
4
Date filed
3/30/2023, 05:00 PM
Previous filing
Mar 24, 2023
Next filing
Dec 12, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common stock, par value $0.001 per share Options Exercise $46K +58.2K +115.15% $0.79* 109K Mar 28, 2023 Direct
transaction CPRX Common stock, par value $0.001 per share Sale -$468K -28.2K -25.94% $16.60 80.6K Mar 28, 2023 Direct F1
transaction CPRX Common stock, par value $0.001 per share Sale -$166K -10K -12.41% $16.55 70.6K Mar 28, 2023 Direct F1
transaction CPRX Common stock, par value $0.001 per share Sale -$165K -10K -14.17% $16.52 60.6K Mar 28, 2023 Direct F1
transaction CPRX Common stock, par value $0.001 per share Sale -$164K -10K -16.51% $16.37 50.6K Mar 28, 2023 Direct F1
transaction CPRX Common stock, par value $0.001 per share Options Exercise $56.5K +50K +98.9% $1.13* 101K Mar 29, 2023 Direct
transaction CPRX Common stock, par value $0.001 per share Sale -$334K -20K -19.89% $16.72 80.6K Mar 29, 2023 Direct F1
transaction CPRX Common stock, par value $0.001 per share Sale -$334K -20K -24.83% $16.70 60.6K Mar 29, 2023 Direct F1
transaction CPRX Common stock, par value $0.001 per share Sale -$167K -10K -16.51% $16.67 50.6K Mar 29, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to purchase common stock Options Exercise $0 -58.2K -4.15% $0.00 1.35M Mar 28, 2023 Common Stock 58.2K $0.79 Direct F2
transaction CPRX Options to purchase common stock Options Exercise $0 -50K -3.72% $0.00 1.3M Mar 29, 2023 Common Stock 50K $1.13 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold to cover exercise price of options, tax withholding requirements and for personal reasons. Shares were not sold as a result of any disagreement with the Company and Ms. Grande remains an officer of the Company.
F2 Options vested in two annual tranches beginning on June 15, 2017.
F3 Options vested in three annual tranches beginning on January 3, 2018.